MA-VERACODE
6.10.2022 13:51:35 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform to include container security. This early access program for Veracode Container Security is now underway for existing customers. The new Veracode Container Security offering, designed to meet the needs of cloud-native software engineering teams, addresses vulnerability scanning, secure configuration, and secrets management requirements for container images.
Veracode Chief Product Officer, Brian Roche, said, “As developers embrace cloud-native computing practices, containers have become increasingly important for business efficiency. This launch helps close a substantial gap in the market for developer-friendly solutions that cover critical capabilities for container security. We are excited to bring this next enhancement of our platform to the market and empower customers to address security testing for more modern architectures and deployment styles.”
The Requirement for Container Security is Rapidly on the Rise
Containers are increasingly used to simplify software deployment and runtime environment configuration management. They comprise small, fast, portable units of software in which code is packaged so that an application can be run quickly and reliably in different computing environments—from the desktop to the cloud. They provide an ecosystem of repositories, orchestration technologies, and capabilities that address related issues, such as service-to-service communication and configuration management. Instantiated in pipelines from code, containers have the benefit of immutability, meaning they are not updated, reconfigured or patched in production. Instead, the underlying image is updated with new capabilities and redeployed, helping to improve efficiency in the production environment.
Despite the benefits of containers, they are affected by many of the same problems that traditionally plague physical production or virtual server hardware, such as vulnerabilities introduced through additional software, poorly managed secrets (like Amazon Web Services keys and credentials in Dockerfiles), and security misconfigurations. This has resulted in increased demand for products that address these issues and related problems, with the Global Container Security Market size expected to reach $3.9 billion by 2027*. Container security scanning analyzes container images against organizational or industry-specific standards to identify insecure processes, misconfigurations that could lead to a vulnerability, and inadequate authentication and access control.
Veracode Container Security Integrates into the Developer Environment
Many products already in the market are aimed at securing containers in runtime and offer limited support for developers, posing a major challenge for early remediation. Veracode’s solution instead integrates into the CI/CD (continuous integration and continuous delivery) pipeline and is available at the command line interface. Providing coverage for vulnerability detection and remediation, secrets management, and security configuration issues on the most popular operating systems, it delivers remediation advice to developers early in the software development life cycle so that insecure containers don’t ship to production.
Veracode Container Security results are available in a variety of formats based on the user’s choice, including text, JSON (JavaScript Object Notation), and Software Bill of Materials (CycloneDX, SWID [Software Identification Tagging], or SPDX [Software Packaging Data Exchange]), making them easy to integrate with other tools. Providing developers and their teams with the tools to meet their specific needs means they can find and fix vulnerabilities early in the lifecycle, giving them confidence that their containerized application environment is secure.
“Veracode Container Security will be instrumental for our developers to ensure that the workloads they deploy into our cloud are secure,” said the Director of Information Security at an automotive company. “Without this tool, it would take our team weeks to receive and action container results and these would only have been available in limited formats. Now, we’re excited to integrate findings into the pipeline before they even move into production, creating time and cost efficiencies for our business.”
To learn more about Container Security, read more here.
*Research and Markets, "Global Container Security Market Size, Share & Industry Trends Analysis Report By Component (Products and Services), By Services Type, By Organization Size, By Vertical, By Regional Outlook and Forecast, 2021-2027" report, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom